Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Payables (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Payables for 14 consecutive years, with $9.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Payables fell 23.19% year-over-year to $9.0 million, compared with a TTM value of $9.0 million through Dec 2025, down 23.19%, and an annual FY2025 reading of $9.0 million, down 23.19% over the prior year.
  • Payables was $9.0 million for Q4 2025 at Heron Therapeutics, down from $12.0 million in the prior quarter.
  • Across five years, Payables topped out at $161.8 million in Q2 2025 and bottomed at $363000.0 in Q4 2022.
  • Average Payables over 5 years is $14.9 million, with a median of $8.6 million recorded in 2022.
  • The sharpest move saw Payables crashed 90.45% in 2022, then soared 1482.66% in 2025.
  • Year by year, Payables stood at $3.8 million in 2021, then plummeted by 90.45% to $363000.0 in 2022, then surged by 792.56% to $3.2 million in 2023, then surged by 261.39% to $11.7 million in 2024, then dropped by 23.19% to $9.0 million in 2025.
  • Business Quant data shows Payables for HRTX at $9.0 million in Q4 2025, $12.0 million in Q3 2025, and $161.8 million in Q2 2025.